Prometheus Biosciences Revenue and Competitors

Claim your profile

Location

#6977

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Prometheus Biosciences's estimated annual revenue is currently $2.6M per year.(i)
  • Prometheus Biosciences's estimated revenue per employee is $25,098
  • Prometheus Biosciences's total funding is $451.8M.
  • Prometheus Biosciences's current valuation is $1.4B. (January 2022)

Employee Data

  • Prometheus Biosciences has 102 Employees.(i)
  • Prometheus Biosciences grew their employee count by 26% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.8M512%$53MN/A
#2
$29.6M125-12%$110MN/A
#3
$0.4M25717%$236.7MN/A
#4
$21.5M114-23%$160MN/A
#5
$3.7M2111%N/AN/A
#6
N/A60150%N/AN/A
#7
$147.3M261-1%$192.5MN/A
#8
$16.6M88-1%$24.1MN/A
#9
$2.7M4018%N/AN/A
#10
$47.1M304-3%N/AN/A
Add Company

Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

keywords:N/A

$451.8M

Total Funding

102

Number of Employees

$2.6M

Revenue (est)

26%

Employee Growth %

$1.4B

Valuation

N/A

Accelerator

Prometheus Biosciences News

2022-04-20 - Prometheus Biosciences Breaks Below 200-Day Moving Average - Notable for RXDX

In trading on Monday, shares of Prometheus Biosciences Inc (Symbol: RXDX) crossed below their 200 day moving average of $31.68,...

2022-04-06 - Difficult-to-treat inflammatory bowel disease: results from a ...

... Cornerstones Health, and Imedex; and as a consultant or adviser to Boehringer Ingelheim, Gilead Sciences, Prometheus Biosciences, Takeda, UCB Biopharma,...

2022-03-30 - Prometheus Biosciences Initiates Third Phase 2 Study of ...

Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD).

2020-12-15 - Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study

SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the diagnosis and treatment of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$33M1026%N/A
#2
$32M102-5%N/A
#3
$669.2M10259%N/A
#4
$11.2M1027%N/A
#5
$32.5M10327%N/A

Prometheus Biosciences Executives


NameTitle
Mark McKennaPresident & CEO, Board Member
Allison LuoChief Medical Officer
Keith MarshallChief Financial Officer
Christopher DoughtyChief Business Officer
Olivier LaurentChief Scientific Officer and Head of R&D
Keith W MarshallChief Financial Officer
Evan McClureChief of Staff & VP, Business Operations
Mark StenhouseChief Operating Officer
Daria UrsolChief Medical Officer
Lauren OtsukiCOO
Mark McKennaPresident & CEO, Board Member
Vika BroughSVP, Finance
Noël KurdiVice President of Investor Relations and Communications
Vika BroughSVP of Finance
MiRa HuygheVP, Clinical Operations
Evan McClureVice President, Corporate Development & Strategy
Chris DoughtySVP of Corporate Development
Noël KurdiVP of Investor Relations and Communications
Evan McClureChief of Staff & VP, Business Operations
Deanna NguyenVice President, Clinical Development